Clinical Trial Update: Effect of MD1003 in Spinal Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

This document provides an update on the Phase 3 trial of MD1003 for spinal progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MD1003 (biotin (high-dose))

Snippet

Sponsor: MedDay Pharmaceuticals SA | Conditions: Multiple Sclerosis | Phase 3 | Status: UNKNOWN